Britny R. Brown

Jun 4, 2024 | pharmacytimes.com | Ryan Haumschild |Heather Moore |Britny R. Brown |Frank Scimeca

2 Commerce Drive Cranbury, NJ 08512

May 28, 2024 | pharmacytimes.com | Ryan Haumschild |Heather Moore |Britny R. Brown |Frank Scimeca

2 Commerce Drive Cranbury, NJ 08512

May 28, 2024 | pharmacytimes.com | Ryan Haumschild |Heather Moore |Britny R. Brown |Frank Scimeca

Exploring Therapeutic Alternatives to CDK4/6 Inhibitors in Metastatic Breast CancerHeather Moore, BCOP, CPP, PharmD, discusses switching from CDK4/6 inhibitors to later lines of therapy, typically due to toxicities, to alleviate symptoms. She emphasizes the goal of finding a new therapy rather than abandoning treatment altogether, and notes that targeted therapy may be necessary in cases of disease progression.